Physician profile
John R Bennett
NPI 1699800227
$1,670.80
in general payments reported to CMS, 2019-2025
16 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $171 · 2021: $98.45 · 2022: $286 · 2023: $270 · 2024: $217 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $506.14 | 2019-2022 | |
| Genzyme Corporation | $300.33 | 2022-2025 | |
| Optinose US, INC. | $286.96 | 2019-2023 | |
| Glaxosmithkline, LLC. | $165.95 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $156.74 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $60.52 | 2019-2024 | |
| Intersect Ent, INC. | $52.22 | 2019-2021 | |
| Cranial Technologies, INC | $25.64 | 2019 | |
| Amgen INC. | $21.51 | 2025 | Tezspire |
| Allergan, INC. | $20.15 | 2021 | |
| Acclarent, INC | $18.06 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2022 | |
| Medtronic, INC. | $15.01 | 2025 | Propel |
| Arbor Pharmaceuticals, INC. | $14.15 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.